Netilmicin sulfate is indicated for the treatment of severe infections caused by sensitive Gram-negative bacilli, including neonatal sepsis, septicemia, central nervous system infections (including meningitis), urinary and reproductive tract infections, respiratory infections, gastrointestinal infections, peritonitis, biliary tract infections, skin or bone infections, otitis media, sinusitis, soft tissue infections, and Listeria monocytogenes disease. It can also be used in combination with other antimicrobials for the treatment of staphylococcal infections. The CDE registration status of Netilmicin sulfate from Fortune Pharmaceuticals is "A," with a production license date of April 22, 2024, and it is currently on the market.